The NADAL® COVID-19 S1-NAb Test serves as an aid in determining whether an immune response to the S1 subunit of the SARS-CoV-2 spike protein has occurred. Antibodies can be detected against vaccines that trigger an immune response against the S1 subunit of the spike protein, such as those from BioNTech/Pfizer, Moderna®, AstraZeneca, Johnson&Johnson and Sinovac Life Sciences.